Retatrutide will likely cost slightly more at launch given its added complexity, but manufacturer savings programs could bring both to similar out-of-pocket costs for eligible patients
GLP-1s are increasingly positioned as chronic maintenance therapies, fundamentally altering lifetime healthcare economics
Scientific references TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial (NEJM, 2023) Retatrutide for people with type 2 diabetes a Phase 2 trial (The Lancet, 2023) LY3437943 (retatrutide), a triple GIP/GLP-1/glucagon agonist Phase 1b trial MHRA: avoid illegal online weight-loss medicines MHRA Drug Safety Update: GLP-1 / GIP agonists pancreatitis warnings NICE TA875: Semaglutide for overweight and obesity NICE TA1026: Tirzepatide for overweight and obesity Incretin-based drugs and gallbladder / biliary disease (The Lancet) Final word for UK research customers A retatrutide 40mg pen is a pre-filled, ready-to-use research peptide with 40mg in the tank roughly 240 clicks, enough for many small doses or a handful of big ones
Read the full story here: What GLP1 users need: Food, nutrition and CPG innovation Nestl signals strategic reset in a shifting market The last month marked a critical moment for Nestl, as its CEO Phillip Navratil outlined a broader strategic overhaul aimed at sharpening focus, restoring growth and responding to changing consumer demand
